AnaptysBio

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $1.41 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Anaptys Announces Participation in November and December Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Anaptys Announces Participation in September Investor Conferences

The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.

Why AnaptysBio Was Such a Healthy Stock This Week

AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.

AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering

Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $1.50 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP), a severe orphan disease that is potentially life-threatening if left untreated.

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli (dostarlimab) royalties. Anaptys intends to utilize the proceeds of the transaction to continue the broad development of its immune cell modulators (ICMs), including its best-in-class checkpoint agonists, in heterogeneous, systemic autoimmune and inflammatory diseases.

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Precigen

XOMA

BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.

Actym Therapeutics Appoints Thomas Smart as CEO

Bitdeer Technologies Group

Theravance Biopharma

The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ: SMCI ) leading the way with a 216% gain so far.

BTIG Research Predicts Over 118% Rally for These 3 Stocks

A major bank initiated coverage of the biotech. It recommended a buy, speculating that the share price could double and then some.

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for AnaptysBio Stock (ANAB)